McGuireWoods partner and host Geoff Cockrell invites colleague Amy Cassalia — whose practice is heavily weighted on life sciences transactions — to share insights about the post-closing period of these complex deals. The wide-ranging conversation covers the dynamics of “contingent consideration,” investor risk and buyers’ leverage.
Amy explains why she sees high-level use of contingent payments in life sciences deals and why the term “commercially reasonable” often becomes critical when a deal spirals into litigation. Stay tuned as she unpacks leading trends. Top among them? The increasing use of earn-outs.